ClinicalTrials.gg
Active, not recruitingNCT07819968Updated Sep 15, 2026

Chronic Patellar Tendinopathy (PT)is Prevalent in Participants of Several Sports.A Three-arm, Single-blind Randomized Controlled Trial Will be Conducted. We Want to Compare the Clinical Effectiveness of ESWT Alone, ESWT Combined With Hyaluronic Acid, and ESWT Combined With PRP in Athletes With PT

An interventional study of Extracorporeal Shock Wave Therapy and Hyaluronic Acid (HA) in Chronic Patellar Tendinopathy, sponsored by Chang Gung Memorial Hospital. Active, not recruiting at 1 site in Taiwan. Open to participants aged 15 Years to 40 Years. Per ClinicalTrials.gov, last updated 2026-09-15.

Sponsored by Chang Gung Memorial Hospital · Not applicable, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
45
Allocation
Randomized
Ages
15 Years to 40 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 14 studies testing platelet rich plasma in Tendinopathy — 2 open to participants now, 4 under way, none of them phase 3. platelet rich plasma · Tendinopathy.

Planned enrollment
9th of 14
45 · median 62
Started
2026
the only one that year
No phase
4 of 14
1 open now
Registered
14th of 14
by date
Lead sponsor
1 of 14
Chang Gung Memorial Hospital

Among the 14 studies testing platelet rich plasma in Tendinopathy, this one is the 9th largest by planned enrollment, is the only one that started in 2026, is one of 4 with no phase, and was the 14th registered.

Tendinopathy

397 studies on the registry are indexed under Tendinopathy; 77 are open to participants now.

Browse Tendinopathy studies →

Open to participants now

2 of the 14 studies testing platelet rich plasma in Tendinopathy are open now, in 2 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 2 open studies →

About platelet rich plasma

No approval found in the FDA or EMA files read. How studies give it is on its page →

Who these studies take

Of the 47 Tendinopathy studies recruiting now, 17 (36%) set no upper age limit and 23 (49%) stop at 75 or younger; 1 takes children under 18; 7 take healthy volunteers.

This study: 15 Years to 40 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 14 studies testing platelet rich plasma in Tendinopathy, or all of them as a file.
02

Study summary

Chronic patellar tendinopathy is highly prevalent among youth, amateur, and elite athletes, with rates reaching 30-40% in high-performance populations. Among current conservative treatments, platelet-rich plasma (PRP) injections and extracorporeal shockwave therapy (ESWT) have demonstrated promising clinical outcomes. However, high-quality randomized controlled trials comparing ESWT alone versus ESWT combined with different injection therapies remain lacking.

Objective:

To compare the clinical effectiveness of ESWT alone, ESWT combined with hyaluronic acid (HA), and ESWT combined with PRP in athletes with chronic patellar tendinopathy.

Methods:

A three-arm, single-blind randomized controlled trial will be conducted. Athletes participating in sports with repetitive jumping or explosive lower-limb loading will be enrolled and stratified by sport type. Inclusion criteria include typical anterior knee pain, a positive decline squat test, and ultrasonographic evidence of tendon thickening or hypoechoic changes. Calcified tendinopathy will be excluded.

Outcomes will be assessed at 1, 3, 6, 9, and 12 months, including VAS, VISA-P, SPORTS scale, sport-specific performance tests (vertical jump, single-leg hop, agility tests), and return-to-play (RTP) time.

Expected Impact:

This study aims to address three key clinical questions:

  1. Is ESWT alone adequate as an initial treatment for chronic patellar tendinopathy in athletes?
  2. If adjunctive injection is needed, does HA or PRP provide superior short- and long-term outcomes?
  3. Which treatment strategy results in the fastest safe return to sport? The findings of this trial will provide evidence-based guidance for clinicians and contribute to the development of more precise treatment algorithms, ultimately enhancing performance longevity and protecting the careers of high-level athletes.
Read the detailed description

1. Research Objective: Chronic patellar tendinitis is a common and highly recurrent sports injury among advanced athletes. Currently, various non-surgical treatments, such as ESWT and PRP injections, are commonly used clinically. However, high-quality randomized controlled trials are lacking regarding whether combined injection therapy is necessary and whether ESWT combined with HA or PRP is more suitable for athletes. This study aims to comprehensively compare the efficacy of ESWT alone versus ESWT combined with either injection therapy through three parallel, stratified, randomized, single-blind clinical trials, providing clinically applicable treatment guidelines.

The objectives of this study are:

  1. To compare the clinical efficacy differences between ESWT alone and ESWT combined with HA/PRP.
  2. To compare the efficacy differences between ESWT combined with HA and ESWT combined with PRP at different time points.
  3. To clarify the impact of different treatment strategies on athletes' return to play (RTP).

2. Research Hypotheses:

  1. ESWT combined with either HA or PRP will be superior to ESWT alone in terms of pain relief (VAS).
  2. ESWT combined with HA will be more effective than ESWT combined with PRP in short-term pain relief. (3) ESWT combined with PRP is superior to ESWT alone or ESWT+HA in terms of mid- to long-term functional improvement, motor performance, and specific tests.

3. Study Endpoints

  1. Primary: Pain improvement at 3 months post-treatment (VAS change from baseline to 3 months)
  2. Secondary: Clinical Symptoms and Function Scales: VAS, VISA-P, SPORTS scale Return to Play (RTP): RTP duration (days), RTP level (complete, playable, with load limitations), relapse rate (12 months)
  3. Ultrasound indicators: thickness and elasticity, size of hypoechoic area, Doppler (neovascularity)

4. Study Design

This study is a prospective clinical trial with three parallel, stratified, randomized, single-blind (subject-blind) groups. The study aimed to compare the clinical efficacy, functional recovery, and return to play (RTP) differences between:

  1. ESWT alone (ESWT + Placebo injection, microdose normal saline)
  2. ESWT combined with hyaluronic acid injection (ESWT+HA)
  3. ESWT combined with high-concentration platelet-plasma injection (ESWT+PRP) in athletes with chronic patellar tendinitis. The study procedure employed a standardized intervention protocol, uniform ultrasound diagnosis and injection site, and fixed ESWT energy settings. All follow-up tests and questionnaire completion were conducted by independent assessors unaware of their assigned groups.
03

Conditions studied

  • Chronic Patellar Tendinopathy

Browse trials for

Keywords

  • Extracorporeal shockwave therapy
  • Hyaluronic acid
  • Platelet-rich plasma
  • Sports medicine
  • Chronic Patellar Tendinopathy
04

Who can participate

Ages eligible
15 Years to 40 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Typical anterior knee pain ≥3 months (chronic stage) Pain location is concentrated at the lower or upper end of the patellar tendon Pain is aggravated by jumping, changing direction, sprinting, squat jumps, or weight-bearing knee extension movements
  2. Typical positive results on physical examination (at least two of the following must be positive):

    Positive Decline squat test Single-leg decline squat pain ≥3/10 Palpation tenderness over patellar tendon (tenderness ≥3/10) Pain induced by Hop test / drop jump

  3. Ultrasound imaging meets the criteria for chronic patellar tendinitis (at least two of the following imaging features must be present):

Patellar tendon thickness >4.0 mm or thicker than the healthy side by ≥15% Hypoechoic area Disorganized fibers Doppler grade 1-2 neovascularity (5) Able to cooperate with research tracking and functional testing

Exclusion criteria

Exclusion Criteria:

  1. Calcified tendinopathy
  2. Acute patellar tendon rupture, partial rupture, or post-operative condition
  3. Received other injectable treatments or high-energy laser/shockwave therapy within the past six months
  4. Systemic diseases including: diseases (e.g., RA, AS), neuromuscular diseases, poorly controlled diabetes ( > 8.5%), blood disorders or currently using anticoagulants (unable to safely receive PRP or injections), infectious diseases
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Participant)
Enrollment
45 participants (estimated)

Study arms

  • Placebo comparator
    ESWT+normal saline

    This group served as the control group in the experimental design, receiving only shockwave therapy. Saline was administered only for the purpose of a single-blind trial.

    Device: Extracorporeal Shock Wave Therapy · Other: Normal Saline

  • Active comparator
    ESWT+hyaluronic acid (HA)

    deliver a gel-like fluid directly into the joint to lubricate cartilage and relieve osteoarthritis pain when basic treatments fail. Hyaluronic acid combined with shockwave therapy aims to achieve effects beyond pain relief.

    Device: Extracorporeal Shock Wave Therapy · Drug: Hyaluronic Acid (HA)

  • Active comparator
    ESWT+Pplatelet-rich plasma (PRP)

    A platelet-rich plasma (PRP) injection is a treatment that uses a high concentration of your own blood platelets to help heal injured joints, tendons, and muscles. The combination of PRP and shockwave therapy is expected to achieve results exceeding those of either treatment alone.

    Device: Extracorporeal Shock Wave Therapy · Biological: Platelet-Rich Plasma

Interventions

  • DeviceExtracorporeal Shock Wave Therapy

    Shockwave therapy is a treatment method that uses high-energy sound waves delivered to body tissues. Through shockwave stimulation of specific frequencies and energy levels, it acts on areas of pain or dysfunction, promoting tissue repair. It is commonly used for chronic musculoskeletal discomfort and sports injury-related problems. In this program, shockwave therapy is the basic treatment, and each experimental group will receiveExtracorporeal Shock Wave Therapy (

  • Hyaluronic acid is primarily used in medicine as an intra-articular injection to relieve pain from osteoarthritis and lubricate joints.

  • PRP (Platelet-Rich Plasma) Brief Introduction and Definition: Concentrated blood plasma rich in platelets and growth factors, extracted from the patient's own blood. Uses: Belonging to regenerative medicine and proliferative therapy, it is commonly used to help repair soft tissues such as muscles, tendons, ligaments, and joints. Principle: Utilizing growth factors from the patient's own blood, it accelerates the healing and regeneration of body tissues.

  • OtherNormal Saline

    Normal saline is a 0.9% sterile aqueous solution of sodium chloride. Its osmotic pressure is similar to that of human blood plasma, and it is widely used in medical and daily care. In this study, it was used as a placebo.

06

What researchers measure

Primary outcomes

  1. Visual Analogue Scale(VAS)

    VAS(Visual Analogue Scale):Ask the patient to mark the degree of their pain on a 10 cm line, from "no pain" on the far left to "unbearable pain" on the far right. The "Numerical Rating Scale" uses a numerical concept of 0-10 points to express the degree of pain, from no pain (0 points) to very painful (10 points).

    Time frame: From enrollment to the end of treatment at 48 weeks

Secondary outcomes

  1. The Victorian Institute of Sport Assessment (VISA-) Patella (P) Questionnaire

    VISA-P: A professional self-assessment tool used to evaluate the severity and treatment effectiveness of patellar tendinopathy. The maximum score is 100 points. A higher score indicates milder symptoms and better function; a lower score indicates a more severe condition. Question Structure: Contains 8 questions. First 6 questions: Assess the degree of pain and functional limitations in specific daily activities (such as sitting, squatting, climbing stairs, hopping on one leg, etc.). Last 2 questions: Assess the level of motor engagement, the ability to train, and the duration of training.

    Time frame: From enrollment to the end of treatment at 48 weeks

  2. SPORTS score (Subjective Patient Outcome for Return to Sports)

    In the fields of sports medicine and orthopedics, the SPORTS scale (Subjective Patient Outcome for Return to Sports score) is a core assessment scale specifically designed to evaluate an athlete's ability to return to sports (RTS) after experiencing a sports injury (such as anterior cruciate ligament rupture, shoulder instability, elbow injury, etc.) and undergoing surgery or treatment. It comprises three independent conceptual constructs: 1) the ability to return to pre-injury intensity and training levels; 2) the ability to achieve the same level of athletic performance; and 3) the ability to achieve 1) and 2 above without pain or with pain relief. This tool uses a 10-point scale, where 0 indicates the patient cannot return to their pre-injury level of athletic performance, and 10 indicates the patient can perform the same sport with the same effort and performance level as before the injury without pain

    Time frame: From enrollment to the end of treatment at 48 weeks

  3. Return to Play (RTP)

    Return to Play (RTP) refers to the complete decision-making process by which athletes safely and gradually return to training and competition after injury or surgery, through medical treatment, physical therapy, and scientific training. RTP comprises three main phases: Return to Participation: Begin non-contact, basic physical and technical rehabilitation training. Return to Sport: Participate in sport-specific movements, simulated competition, and team training. Return to Performance: Recover to the pre-injury competitive level and peak performance.

    Time frame: From enrollment to the end of treatment at 48 weeks

Other outcomes

  1. Ultrasound Assessment: Joint Effusion

    Measurement of joint effusion in the knee joint using ultrasound examination. Unit of Measure: millimeter(mm)

    Time frame: From enrollment to the end of treatment at 48 weeks

  2. Ultrasound Assessment: Medial Meniscus (MM) Extrusions Width at Full Extension

    Measurement of medial meniscus extrusion width at full extension using ultrasound examination.Unit of Measure: millimeter(mm)

    Time frame: From enrollment to the end of treatment at 48 weeks

  3. Ultrasound Assessment: Medial Meniscus (MM) Extrusion Width at Standing Weight-Bearing

    Measurement of medial meniscus extrusion width during standing weight-bearing using ultrasound examination.Unit of Measure: millimeter(mm)

    Time frame: From enrollment to the end of treatment at 48 weeks

  4. Ultrasound Assessment: Medial Collateral Ligament (MCL) Thickness at Full Extension

    Measurement of medial collateral ligament thickness at full extension using ultrasound examination.Unit of Measure: millimeter(mm)

    Time frame: From enrollment to the end of treatment at 48 weeks

  5. Ultrasound Assessment: Doppler Signal at Medial Meniscus (MM) Body

    Assessment of vascularization and inflammation via Doppler ultrasound signal at the medial meniscus body.

    Time frame: Unit of Measure: (Semi-quantitative scale, 0-3)

07

Study locations

1 site
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Sep 2026 (actual). Primary completion is estimated for Jul 2027, 10 months after the start.

Of 173 non-industry interventional studies with no phase under Tendinopathy, half reached primary completion within 20 months of starting (the median), counting those still running; a quarter within 7 and three quarters within 37. This study's planned 10 months is below that.

Counting every sponsor, half of 182 studies reached it within 20 months; a quarter within 7 and three quarters within 37.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 3, 2026
First posted
Sep 15, 2026
StartActual
Sep 1, 2026
Primary completionEst.
Jul 31, 2027
CompletionEst.
Jul 31, 2028
Last update
Sep 15, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 15, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT07819968
Responsible party
Sponsor
First posted
Sep 15, 2026
Start date
Sep 1, 2026
Primary completion
Jul 31, 2027 (estimated)
Completion
Jul 31, 2028 (estimated)
Last update
Sep 15, 2026

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Hyaluronic Acid · Platelet rich plasma

Start the discussion